Medeor Therapeutics Overview
- Founded
- 2012
- Status
- Private
- Latest Deal Type
- Debt - PPP
- Investors
- 6
Medeor Therapeutics General Information
Description
Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.
Contact Information
Website
www.medeortx.com
Formerly Known As
SERC Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 611 Gateway Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Medeor Therapeutics Timeline
Medeor Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Debt - PPP | 29-Apr-2020 | 000.00 | Completed | Generating Revenue | ||
| 5. Grant | 22-Jan-2018 | 000.00 | 000.00 | Completed | Generating Revenue | |
| 4. Early Stage VC (Series B) | 27-Nov-2017 | 0000 | 000.00 | 00000 | Completed | Generating Revenue |
| 3. Early Stage VC (Series A) | 16-Oct-2015 | 000 | 000.00 | 0000 | Completed | Generating Revenue |
| 2. Early Stage VC | 02-Oct-2013 | $1.55M | $2.55M | 000.00 | Completed | Generating Revenue |
| 1. Seed Round | 11-Jan-2013 | $1M | $1M | 000 | Completed | Generating Revenue |
Medeor Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
| Series A | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Seed 1 | 1,291,667 | $0.000100 | 8% | $1.2 | $1.2 | 1x | $1.2 | 4.67% |
| Seed | 1,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 3.61% |
Medeor Therapeutics Patents
Medeor Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200086004-A1 | Methods of making cellular compositions derived from deceased donors to promote graft tolerance | Pending | 18-Sep-2018 | 00000000000 | |
| US-20200086006-A1 | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof | Pending | 18-Sep-2018 | 0000000000 | |
| US-20200087627-A1 | Methods of extracting hematopoietic cells from bone marrow ex vivo | Pending | 18-Sep-2018 | 0000000000 | |
| US-20200088718-A1 | Methods of analysis of blood from deceased donors | Pending | 18-Sep-2018 | 00000000000 | |
| US-10842821-B2 | Cellular compositions derived from prior organ donors and methods of manufacture and use thereof | Active | 05-Apr-2018 | A61K35/28 |
Medeor Therapeutics Executive Team (14)
Medeor Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anand Mehra MD | Sofinnova Investments | Board Member | 000 0000 |
| Chih-Ping Liu Ph.D | Self | Co-Founder and Chairman | 000 0000 |
| Frank Kung Ph.D | Vivo Capital | Board Member | 000 0000 |
| Peter Kolchinsky Ph.D | RA Capital Management | Board Observer | 000 0000 |
| Wei Li Ph.D | WuXi Healthcare Ventures | Board Member | 000 0000 |
Medeor Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine | Government | 000 0000 | 000000 0 | ||
| 6 Dimensions Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| RA Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Sofinnova Investments | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Vivo Capital | Venture Capital | Minority | 000 0000 | 000000 0 |